Published in Breast Cancer Res Treat on April 15, 2016
Axillary dissection versus no axillary dissection in patients with sentinel-node micrometastases (IBCSG 23-01): a phase 3 randomised controlled trial. Lancet Oncol (2013) 6.79
Sentinel lymph node biopsy: is it indicated in patients with high-risk ductal carcinoma-in-situ and ductal carcinoma-in-situ with microinvasion? Ann Surg Oncol (2000) 3.75
Importance of lymphatic mapping in ductal carcinoma in situ (DCIS): why map DCIS? Am Surg (2001) 1.87
The relevance of occult axillary micrometastasis in ductal carcinoma in situ: a clinicopathologic study with long-term follow-up. Cancer (2003) 1.79
Axillary sentinel lymph node biopsy in patients with pure ductal carcinoma in situ of the breast. Arch Surg (2003) 1.63
Ductal carcinoma in situ at core-needle biopsy: meta-analysis of underestimation and predictors of invasive breast cancer. Radiology (2011) 1.59
Sentinel node biopsy for nonpalpable breast tumors requires a preoperative diagnosis of invasive breast cancer. Breast J (2003) 1.44
Sentinel node biopsy in ductal carcinoma in situ patients. Ann Surg Oncol (2000) 1.38
Best Practice No 179. Guidelines for breast needle core biopsy handling and reporting in breast screening assessment. J Clin Pathol (2004) 1.07
Axillary lymph node dissection for intraductal breast carcinoma--is it indicated? Cancer (1987) 1.02
Core biopsy diagnosis of ductal carcinoma in situ: an indication for sentinel lymph node biopsy. Curr Surg (2005) 1.00
Axillary lymph node metastases in patients with a final diagnosis of ductal carcinoma in situ. Am J Surg (2003) 0.99
Feasibility of a prospective, randomised, open-label, international multicentre, phase III, non-inferiority trial to assess the safety of active surveillance for low risk ductal carcinoma in situ - The LORD study. Eur J Cancer (2015) 0.94
Risk of invasion and axillary lymph node metastasis in ductal carcinoma in situ diagnosed by core-needle biopsy. Br J Surg (2007) 0.92
Diagnosis and treatment of early breast cancer, including locally advanced disease--summary of NICE guidance. BMJ (2009) 0.91
Sentinel lymph node biopsy for ductal carcinoma in situ: an evolving approach at the University of Florida. Breast J (2005) 0.90
Sentinel lymph node biopsy for localised ductal carcinoma in situ? Breast (2005) 0.90
An argument against routine sentinel node mapping for DCIS. Am Surg (2004) 0.86
Is there an indication for sentinel node biopsy in patients with ductal carcinoma in situ of the breast? A review. Eur J Cancer (2007) 0.86
Lymph node metastasis from ductal carcinoma in situ with microinvasion. Cancer (1999) 0.85
Is Sentinel Lymph Node Dissection Warranted for Patients with a Diagnosis of Ductal Carcinoma In Situ? Ann Surg Oncol (2015) 0.82
The incidence and significance of micrometastases in lymph nodes of patients with ductal carcinoma in situ and T1a carcinoma of the breast. Eur J Surg Oncol (2006) 0.82
Sentinel lymph node biopsy as a tool for the staging of ductal carcinoma in situ in patients with breast carcinoma. Surg Today (2002) 0.81
A comparison of the accuracy of two minimally invasive breast biopsy methods: a systematic literature review and meta-analysis. Arch Gynecol Obstet (2006) 0.81
ACR Appropriateness Criteria® Ductal Carcinoma in Situ. Oncology (Williston Park) (2015) 0.79
Carcinoma in situ. BMJ (2013) 0.77
Sentinel lymph node biopsy is not warranted following a core needle biopsy diagnosis of ductal carcinoma in situ (DCIS) of the breast. Breast (2015) 0.77
Combined PET-CT and axillary lymph node marking with radioactive iodine seeds (MARI procedure) for tailored axillary treatment in node-positive breast cancer after neoadjuvant therapy. Br J Surg (2017) 0.75
CTNNB1-mutated melanocytic lesions with DPN like features: a distinct subtype of melanocytic tumors? A report of two cases. Virchows Arch (2017) 0.75